摘要
基于氟尿嘧啶的术前同期放化疗是局部进展期直肠癌标准治疗模式，而探讨新化疗药物如希罗达、奥沙利铂、伊立替康、贝伐单抗和西妥昔单抗在其新辅助放化疗中的作用越来越引起人们兴趣，并开展了一系列Ⅰ-Ⅲ期临床研究，部分取得了积极结果，而有些并不理想。希罗达在局部进展期直肠癌新辅助放化疗中的地位已普遍获得公认．且有取代常规氟尿嘧啶趋势，而奥沙利铂、伊立替康及生物靶向类药物在其中的作用却存在明确争议，临床获益有限。彼此药物之间或靶点药物与放射线之间的相互作用机制研究、新的治疗反应预测靶点及合适个体的筛选可能是今后发展方向。
Preoperative concurrent chemoradiotherapy based on 5-fluorouraeil （5-FU） is an standard treatment mode for patients with locally advanced rectal cancer （LARC）. Currently, more and more interests has now focused on new chemotherapeutic drugs, such as eapeeitabine, oxaliplatin, irinotecan, bevacizumab, and cetuximab in this treatment mode. Many prospective phase I -111 clinical trials have been developed to explore these new drugs efficacy in the neoadjuvant chemoradiation （nCRT） for patients with LARC. Some results are very encouraging, yet others are undesirable. Capeeitabine has been widely recognized in the nCRT for patients with LARC, and has the tendency to replace 5-FU. However, there are some controversies for oxaliplatin, irinotecan, and biologically targeted drugs in the nCRT mode because of their limited clinical benefits. It is potentially thedevelopment direction to study the mutual interaction mechanism among concurrent drugs or radiation and biologically targeted drugs, find new predicatively responsive targets, and screen the appropriate patient in the treatment of neoCRT for patients with LARC in the future.
出处
《中华胃肠外科杂志》
CAS
CSCD
2014年第1期93-97,共5页
Chinese Journal of Gastrointestinal Surgery
关键词
局部进展期直肠癌
新辅助放化疗
氟尿嘧啶
Locallyadvancedrectalcancer
Neoadjuvantehemoradiation therapy
5-Fluorouracil
